



IPI-3063

Catalog No: tcsc0042285

Available Sizes
ize: 2mg
ize: 5mg
ize: 10mg
ize: 25mg
Specifications
AS No: 425043-73-7
ormula: 25 ^H 25 ^N 7 ^O 2
athway: 3K/Akt/mTOR
arget: 3K
urity / Grade: 98%
olubility: MSO : ≥ 83.33 mg/mL (182.94 mM)
bserved Molecular Weight: 55.51

Product Description

IPI-3063 is a potent and selective **PI3K p1106** inhibitor with an IC_{50} of 2.5 \pm 1.2 nM.





IC50 & Target: IC50: 2.5 ± 1.2 nM (p110 δ), 1171 ± 533 nM (p110 α), 1508 ± 624 nM (p110 β), 2187 ± 1529 nM (p110 γ) [1]

In Vitro: IPI-3063 inhibits p110α, p110β, and p110γ with IC $_{50}$ s of 1171±533 nM, 1508±624 nM, and 2187±1529 nM, respectively. IPI-3063 potently reduces mouse B cell proliferation, survival, and plasmablast differentiation while increasing antibody class switching to IgG1. IPI-3063 is a p110δ selective compound with an IC $_{50}$ =0.1 nM in p110δ-specific cell-based assays and cellular IC $_{50}$ values for the other class I PI3K isoforms are at least 1,000-fold higher (IC $_{50}$ =1901±1318 nM for p110α, IC $_{50}$ =102.8±35.7 nM for p110β, IC $_{50}$ =418.8±117.2 nM for p110γ). IPI-3063 is very potent in reducing p-AKT (significant effect at 1 nM). IPI-3063 also reduces p-ERK1/2 with a significant effect at 10 nM. IPI-3063 is very potent, achieving a significant decrease in B cell survival when present at 10 nM^[1].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!